Safety and Protective Efficacy of Pb(PfCS@UIS4) (PbVac)
Safety and Protective Efficacy of Genetically Modified Plasmodium Berghei (Pb(PfCS@UIS4)) Malaria Parasites in Healthy Volunteers
Sponsor: Erasmus Medical Center
This PHASE1/PHASE2 trial investigates Controlled Human Malaria Infection (CHMI) and Malaria,Falciparum and is currently completed. Erasmus Medical Center leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Apr 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Mar 2022 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE1_PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Havenziekenhuis
- Radboud University Medical Center
- The PATH Malaria Vaccine Initiative (MVI)
For direct contact, visit the study record on ClinicalTrials.gov .